Cargando…

Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients

PURPOSE: To determine compliance rates and characteristics and to investigate factors affecting patients’ adherence to treatment with anti-vascular endothelial growth factors (anti-VEGFs) for diabetic macular edema (DME) in a cohort of Jordanian patients. METHODS: A retrospective case series wherein...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Yaghi, Nakhleh E, Abed, Alaa M, Khlaifat, Dana F, Nawaiseh, Mohammed B, Emoush, Laith O, AlHajjaj, Heba Z, Abojaradeh, Ala M, Hattar, Mariana N, Abusaleem, Sura K, Sabbagh, Hashem M, Abu Gharbieh, Yazan A, Quaqazeh, Sura A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102883/
https://www.ncbi.nlm.nih.gov/pubmed/32273676
http://dx.doi.org/10.2147/OPTH.S248661
_version_ 1783511932966273024
author Abu-Yaghi, Nakhleh E
Abed, Alaa M
Khlaifat, Dana F
Nawaiseh, Mohammed B
Emoush, Laith O
AlHajjaj, Heba Z
Abojaradeh, Ala M
Hattar, Mariana N
Abusaleem, Sura K
Sabbagh, Hashem M
Abu Gharbieh, Yazan A
Quaqazeh, Sura A
author_facet Abu-Yaghi, Nakhleh E
Abed, Alaa M
Khlaifat, Dana F
Nawaiseh, Mohammed B
Emoush, Laith O
AlHajjaj, Heba Z
Abojaradeh, Ala M
Hattar, Mariana N
Abusaleem, Sura K
Sabbagh, Hashem M
Abu Gharbieh, Yazan A
Quaqazeh, Sura A
author_sort Abu-Yaghi, Nakhleh E
collection PubMed
description PURPOSE: To determine compliance rates and characteristics and to investigate factors affecting patients’ adherence to treatment with anti-vascular endothelial growth factors (anti-VEGFs) for diabetic macular edema (DME) in a cohort of Jordanian patients. METHODS: A retrospective case series wherein the files of DME patients treated with anti-VEGFs were reviewed and analyzed for factors affecting treatment compliance was undertaken. Demographic, clinical and ocular characteristics were recorded. All patients were also interviewed by phone using a structured questionnaire. Univariate and multivariate analyses were performed to determine factors associated with compliance. RESULTS: A total of 117 patients (65 males 52 females) were included in this study with a mean age of 62.93 years (±9.75). Approximately, 85% of patients were compliant to their treatment and follow-up plan during the first year of management. Subjective perception of visual improvement after receiving three loading doses was the only independent variable with a unique statistically significant contribution to compliance. All other studied factors in this group of patients were not significantly associated with patient compliance. CONCLUSION: VEGF suppression via the intravitreal route to treat DME is a long-term process that requires caregiver dedication but also proper patient compliance. Addressing real-life barriers in those patients may help guide future strategies to improve the treatment experience, lower the financial burden and contribute to better outcomes. Patients' perceptions of possible treatment outcomes at the short term may influence their long-term commitment to therapy.
format Online
Article
Text
id pubmed-7102883
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-71028832020-04-09 Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients Abu-Yaghi, Nakhleh E Abed, Alaa M Khlaifat, Dana F Nawaiseh, Mohammed B Emoush, Laith O AlHajjaj, Heba Z Abojaradeh, Ala M Hattar, Mariana N Abusaleem, Sura K Sabbagh, Hashem M Abu Gharbieh, Yazan A Quaqazeh, Sura A Clin Ophthalmol Original Research PURPOSE: To determine compliance rates and characteristics and to investigate factors affecting patients’ adherence to treatment with anti-vascular endothelial growth factors (anti-VEGFs) for diabetic macular edema (DME) in a cohort of Jordanian patients. METHODS: A retrospective case series wherein the files of DME patients treated with anti-VEGFs were reviewed and analyzed for factors affecting treatment compliance was undertaken. Demographic, clinical and ocular characteristics were recorded. All patients were also interviewed by phone using a structured questionnaire. Univariate and multivariate analyses were performed to determine factors associated with compliance. RESULTS: A total of 117 patients (65 males 52 females) were included in this study with a mean age of 62.93 years (±9.75). Approximately, 85% of patients were compliant to their treatment and follow-up plan during the first year of management. Subjective perception of visual improvement after receiving three loading doses was the only independent variable with a unique statistically significant contribution to compliance. All other studied factors in this group of patients were not significantly associated with patient compliance. CONCLUSION: VEGF suppression via the intravitreal route to treat DME is a long-term process that requires caregiver dedication but also proper patient compliance. Addressing real-life barriers in those patients may help guide future strategies to improve the treatment experience, lower the financial burden and contribute to better outcomes. Patients' perceptions of possible treatment outcomes at the short term may influence their long-term commitment to therapy. Dove 2020-03-24 /pmc/articles/PMC7102883/ /pubmed/32273676 http://dx.doi.org/10.2147/OPTH.S248661 Text en © 2020 Abu-Yaghi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Abu-Yaghi, Nakhleh E
Abed, Alaa M
Khlaifat, Dana F
Nawaiseh, Mohammed B
Emoush, Laith O
AlHajjaj, Heba Z
Abojaradeh, Ala M
Hattar, Mariana N
Abusaleem, Sura K
Sabbagh, Hashem M
Abu Gharbieh, Yazan A
Quaqazeh, Sura A
Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
title Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
title_full Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
title_fullStr Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
title_full_unstemmed Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
title_short Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients
title_sort factors affecting compliance to anti-vascular endothelial growth factor treatment of diabetic macular edema in a cohort of jordanian patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102883/
https://www.ncbi.nlm.nih.gov/pubmed/32273676
http://dx.doi.org/10.2147/OPTH.S248661
work_keys_str_mv AT abuyaghinakhlehe factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT abedalaam factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT khlaifatdanaf factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT nawaisehmohammedb factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT emoushlaitho factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT alhajjajhebaz factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT abojaradehalam factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT hattarmarianan factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT abusaleemsurak factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT sabbaghhashemm factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT abugharbiehyazana factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients
AT quaqazehsuraa factorsaffectingcompliancetoantivascularendothelialgrowthfactortreatmentofdiabeticmacularedemainacohortofjordanianpatients